Alto Neuroscience, Inc.

NYSE:ANRO

Biotechnology

Healthcare
$25.91 +1.84%

+$0.40 today

Market cap
$1.04B
Beta
1.25
P/E (TTM)
-9.8
EPS (TTM)
-$2.26
52W Low $2.15High $28.44

Volume 0.99M

Average 0.34M

ANRO Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Alto Neuroscience, Inc.NYSE: ANRO

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 32.89M shares rose 21.6% year over year, ahead of the +10.2% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 3.0% from the prior quarter. Over 3 fiscal years it compounded at +4.1% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +21.6% holds above the trailing-twelve-month pace of +10.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
32.89M+3.0% QoQ
Last fiscal yearDec 2025
28.85M+17.3% YoY
LTMMar 2026
29.75M+10.2% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.6%——
1 year+17.3%——
3-year CAGR+4.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
28.85M USD
Year-over-year change
+17.3%
4-year CAGR
+3.1%

Weighted Avg Shares vs competitors

How ANRO compares with its peers on the latest reported figures

  • ANRO's LTM Mar 2026 weighted avg shares of 29.75M shares is the 9th highest of the 11 companies compared; the peer median is 69.17M shares.
  • Its year-over-year change of +10.2% is the 4th highest of 10, against a peer median of +2.9%.
  • Over three fiscal years its annual growth of +4.1% compares with a peer median of +7.3%.
ANRO Competitors Peer median
Weighted Avg Shares for ANRO and competitors
Company Period LTM YoY 3-year CAGR
CLLSCellectis S.A.LTM Mar 2026100.38M +2.9%+30.1%
ACIUAC Immune S.A.LTM Mar 202699.9M -2.5%+6.4%
DBVTDBV Technologies S.A.LTM Mar 202688.66M -7.8%+3.7%
DRTSAlpha Tau Medical Ltd.LTM Mar 202684.87M +21.1%+8.2%
LRMRLarimar Therapeutics, Inc.LTM Mar 202678.18M +22.5%+41.5%
ALDXAldeyra Therapeutics, Inc.LTM Mar 202660.16M +1.0%+0.9%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 202630.55M +18.4%+3.3%
ANROAlto Neuroscience, Inc.LTM Mar 202629.75M +10.2%+4.1%
AMRNAmarin Corporation plcLTM Mar 202620.78M +1.0%+1.1%
KRROKorro Bio, Inc.LTM Mar 20269.94M +8.7%+232.8%
Peer median (excluding ANRO) 69.17M+2.9%+7.3%

Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue210K0000
Cost of Revenue145K342K0502K661K
Gross Profit65K(342K)0(502K)(661K)
Gross Margin31.0%————
Research & Development8.37M23.69M30.29M47M45.62M
Selling, General & Admin3.75M5.16M7.52M21.61M20.75M
Operating Expenses12.12M28.85M37.81M68.11M65.7M
Depreciation & Amortization145K342K373K502K661K
EBITDA(9.04M)(27.37M)(34.56M)(62.3M)(60.11M)
EBITDA Margin-4305.7%————
Operating Income(12.06M)(29.19M)(37.81M)(68.61M)(66.36M)
Operating Margin-5741.0%————
Interest Income2K114K2.35M8.85M6.6M
Interest Expense001.37M(1.38M)2.47M
Other Income / Expenses2.87M1.48M1.5M7.18M3.13M
Income Before Tax(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Pre-Tax Margin-4374.8%————
Income Tax Expense00000
Net Income(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Net Margin-4374.8%————
EPS (Basic)(0.36)(1.08)(1.35)(2.50)(2.19)
EPS (Diluted)(0.36)(1.08)(1.35)(2.50)(2.19)
Weighted Avg Shares25.57M25.57M26.88M24.6M28.85M
Weighted Avg Shares (Diluted)25.57M25.57M26.88M24.6M28.85M

Alto Neuroscience, Inc.

NYSE:ANRO

Intrinsic Alpha fair value

Locked

Current Price

$25.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.